Literature DB >> 33880573

Beneficial Impact of Apremilast on Palmoplantar Keratodermas.

Kimiko Nakajima1, Riho Nakajima, Hiroyuki Morisaka, Hideki Nakajima, Shigetoshi Sano.   

Abstract

Entities:  

Keywords:  apremilast; psoriasis; palmoplantar keratodermas

Mesh：

Substances：

Year:  2021        PMID： 33880573      PMCID： PMC9364248          DOI： 10.2340/00015555-3805

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  15 in total

1.  Biologic therapy targeting IL-17 ameliorates a case of congenital ichthyosiform cornification disorder.

Authors:  Daniela Haiges; Judith Fischer; Steffen Hörer; Cristina Has; Christoph M Schempp
Journal:  J Dtsch Dermatol Ges       Date:  2018-12-03       Impact factor: 5.584

2.  Phosphodiesterase-4 inhibitors reduce the expression of proinflammatory mediators by human epidermal keratinocytes independent of intracellular cAMP elevation.

Authors:  Sayo Kataoka; Mikiro Takaishi; Kimiko Nakajima; Shigetoshi Sano
Journal:  J Dermatol Sci       Date:  2020-10-06       Impact factor: 4.563

3.  Pityriasis rubra pilaris and vitiligo in Down's syndrome.

Authors:  A R Hazini; F Rongioletti; A Rebora
Journal:  Clin Exp Dermatol       Date:  1988-09       Impact factor: 3.470

Review 4.  Mechanisms Underlying the Clinical Effects of Apremilast for Psoriasis.

Authors:  Carlo Pincelli; Peter H Schafer; Lars E French; Matthias Augustin; James G Krueger
Journal:  J Drugs Dermatol       Date:  2018-08-01       Impact factor: 2.114

5.  Favorable response to apremilast in a patient with refractory psoriasis verrucosa.

Authors:  Sari Okazaki; Risa Osawa; Hideki Nakajima; Kimiko Nakajima; Shigetoshi Sano
Journal:  J Dermatol       Date:  2019-04-08       Impact factor: 4.005

6.  Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis.

Authors:  P H Schafer; A Parton; A K Gandhi; L Capone; M Adams; L Wu; J B Bartlett; M A Loveland; A Gilhar; Y-F Cheung; G S Baillie; M D Houslay; H-W Man; G W Muller; D I Stirling
Journal:  Br J Pharmacol       Date:  2009-12-24       Impact factor: 8.739

7.  Classical juvenile pityriasis rubra pilaris in a patient with Down syndrome.

Authors:  K Terasaki; T Kanekura; H Saruwatari; T Kanzaki
Journal:  Clin Exp Dermatol       Date:  2004-01       Impact factor: 3.470

8.  Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study.

Authors:  R Bissonnette; R Haydey; L A Rosoph; C W Lynde; M Bukhalo; J F Fowler; I Delorme; A Gagné-Henley; M Gooderham; Y Poulin; K Barber; P Jenkin; I Landells; D M Pariser
Journal:  J Eur Acad Dermatol Venereol       Date:  2017-11-15       Impact factor: 6.166

9.  Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast.

Authors:  Ifat Zerin Krase; Kevin Cavanaugh; Clara Curiel-Lewandrowski
Journal:  JAMA Dermatol       Date:  2016-03       Impact factor: 10.282

10.  Interleukin 23-Helper T Cell 17 Axis as a Treatment Target for Pityriasis Rubra Pilaris.

Authors:  Laurence Feldmeyer; Alessio Mylonas; Olivier Demaria; Anna Mennella; Nikhil Yawalkar; Emmanuel Laffitte; Daniel Hohl; Michel Gilliet; Curdin Conrad
Journal:  JAMA Dermatol       Date:  2017-04-01       Impact factor: 10.282
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.